| The Company has forayed into the growing diabetic market, with the intent of tapping the Indian Diabetology market in an optimised manner through the Lupin Diabetes Care division in 2004. Lupin has devised a distinctive product range catering to the therapeutic areas of diabetes as well as related complications. Its core portfolio of offerings revolves around the OHA products, which are Oral Diabetes Agents. The division also encompasses the Diabetes Neuropathy Management basket. Additionally, the Company has strategically included a spectrum of cardio-products such as, Diabetic Anti-hypertensive and Diabetic Dislipidemic drugs, as part of its portfolio under this category. ORG estimates the Diabetic market to be valued at Rs.11,128
mn with a growth rate of 22.3%. Lupin has been growing faster than the market and has secured a position amongst the top 10 in this segment.. This division has registered the fastest growth rate in the IPM amongst the market leaders.
Key Products : Lupin Diabetes Care
|
Product |
Therapeutic Segment |
Product Rank in the relevant segment |
|
Misobit |
Miglitol |
1 |
|
Telista |
Telmisartan |
2 |
|
Gabastar |
Gabapentin |
2 |
|
Matilda |
Mecobalamin |
2 |
|
Lipril |
Lisinopril |
2 |
|
Gluconorm |
Diabetics orals |
3 |
| 
